RxDoctor Payments Data

Evelyn Norton

Psychiatric/Mental Health · Chicago, ILNPI 1629312483

Payments from drug & device makers

$3,731in general payments, 2019–2025

Across 59 payments — averaging $63.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$985
  • Teva Pharmaceuticals USA, Inc.$806
  • AbbVie$624
  • Neurocrine Biosciences, Inc.$569
  • E.r. Squibb & Sons, L.L.C.$278
  • Alkermes, Inc.$220
  • plus $249 from 3 others

What the payments were for

  • Food & beverage$3,52094%
  • Education$2116%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,731 in reported general payments places this provider in the 90th percentile of 922 psychiatric/mental health providers in Illinois.

See all psychiatric/mental health providers in Illinois

Medicare billing

Part B allowed, 2024
$25,286
Medicare patients
84
Services billed
346

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega TrinzaPaliperidone Palmitate31$225,413
IngrezzaValbenazine Tosylate14$111,512
Abilify MaintenaAripiprazole41$107,706
Invega SustennaPaliperidone Palmitate28$67,642
PerserisRisperidone20$45,953
VraylarCariprazine Hcl20$32,064
Lurasidone Hcl26$6,671
TrintellixVortioxetine Hydrobromide14$6,494
Quetiapine Fumarate128$2,453
Divalproex Sodium ErDivalproex Sodium28$1,582
Sertraline Hcl184$1,512
Aripiprazole40$1,326
Fluoxetine Hcl52$1,124
Buspirone Hcl72$1,057
Bupropion XlBupropion Hcl48$1,003

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Trinza, Invega Sustenna$985$293,05559 claims
Neurocrine Biosciences, Inc.Ingrezza$569$111,51214 claims
AbbVieVraylar$624$32,06420 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 922 psychiatric/mental health providers in Illinois.

Other psychiatric/mental health in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →